Erasca reports Phase 1 data for ERAS-0015 in KRAS-mutant tumors

July 13, 2026 4:01 PM

Erasca, Inc. (Nasdaq: ERAS) released updated preliminary Phase 1 data for its investigational pan-RAS molecular glue ERAS-0015 in patients with ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found